Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996

Santos, Boaventura Antônio dos; Stralioto, Selir M.; Siqueira, Marilda Mendonça; Ranieri, Tani Schilling; Bercini, Marilina; Schermann, Maria Tereza; Wagner, Mário Bernardes; Silveira, Themis Reverbel da

doi:10.1590/s1020-49892006001000002

Cited by 8 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison to a previous study in South Africa which reported 9% of children with meningitis to have mumps virus, the reported seropositivity in this current study is indeed high [20]. When compared to previous studies in other countries outside Africa; the reported seropositivity in the current study is low compared to 80.2%, 71.9%, 89.1, 71.1 and 69.4% reported in Iran, Yemen, Ankara Turkey, Eastern Turkey and Brazil, respectively [1,18,24,29,30]. The possible explanation for these variations could be due to differences in seasonality, study populations, geographical and climatic conditions.…”

Section: Discussionsupporting

confidence: 45%

High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?

Rakiru

Msanga

Laisser

et al. 2020

IJTDH

View full text Add to dashboard Cite

Aim: This study for the first time in Mwanza, Tanzania aimed at determining seropositivity of mumps virus in school aged children who are targeted for vaccination. Study Design: Cross-sectional study. Place and Duration of the Study: This study was conducted in the city of Mwanza from July to September 2018. Despite being common with reported associated complications in many resource limited countries, there is scarcity of information on its epidemiology in Tanzania. Methodology: We enrolled 440 school children aged 6-12 years. Data was collected using a pre-tested structured data collection tool. Blood samples were collected, and sera were used for detection of mumps virus antibodies by indirect enzyme linked immunosorbent assay (ELISA). Data was analyzed using STATA version 13, 2013. Results: The median age of enrolled children was 9(IQR: 8-11) years. The seropositivity of mumps IgG antibodies was found to be 94(21.4%, 95% CI: 17.5-25.1) while that of IgM was 1 (0.23%, 95% CI: 0.02-0.6). By multivariable logistic regression analysis, residing in rural areas (OR: 2.28, 95% 1.42-3.36, P=0.001) and age >10 years (OR: 1.67, 95% CI: 1.03-2.7, P=0.036) independently predicted mumps IgG seropositivity. Conclusion: A significant proportion of young children in urban areas of the city of Mwanza are susceptible to mumps virus infection indicating the need to generate more data across the country so as to institute appropriate control measures including measles, mumps and rubella (MMR) vaccination programme.

show abstract

Section: Discussionsupporting

confidence: 45%

High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?

Rakiru

Msanga

Laisser

et al. 2020

IJTDH

View full text Add to dashboard Cite

show abstract

“…These studies were conducted in Brazil (1), Mexico (3), Sweden (1), the U.S., and U.S./Europe (1). [14][15][16][17][18][19][20] The mean age of participants ranged from 7 to 26 years (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Use of M-M-R II outside of the routinely recommended age range – a systematic literature review

Pawaskar

Schmidt²,

Marshall

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

M-M-R® II (M-M-R II) is routinely used in many countries at 12-15 months with a second dose at 4 to 6 years of age. However, the vaccine may need to be administered at other ages due to delays in the immunization schedule or in certain situations such as outbreaks or international travel. A systematic literature review was conducted to evaluate efficacy, immunogenicity and safety of M-M-R II among 6-to 11-montholds and persons ≥7 years of age. A search for randomized controlled trials (RCTs) was conducted in 2019 including Medline, Embase and Cochrane CENTRAL. Only one study reported seroconversion rates after one dose in infants at 9 months of age: 87.4% (measles), 92.3% (mumps), and 91.2% (rubella); no safety data were reported. Seven studies reported immunogenicity and safety data for M-M-R II at ≥7 years of age. Seroconversion rates ranged from 96%-100% (measles), 65%-100% (mumps), and 91%-100% (rubella). Rates of selected adverse events ranged from 5.2%-8.7% for fever (≥38°C or ≥38.1°C), 2%-33.3% for injection site reactions, and 0.4% for measles/rubella-like rash (one study). No efficacy studies were found. This literature review identified RCTs with evidence to support that M-M-R II is immunogenic and well tolerated in individuals ≥7 years of age.

show abstract

“…We identified over 220 studies that provided cross‐sectional data and nearly 180 studies that reported on immunity for women of child‐bearing age, primarily for rubella. Table summarizes the over 400 cross‐sectional and women of child‐bearing age measles and rubella serological studies…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Measles and Rubella Serology Studies

Thompson

Odahowski²

2015

Risk Analysis

View full text Add to dashboard Cite

Serological tests provide information about individual immunity from historical infection or immunization. Cross-sectional serological studies provide data about the age- and sex-specific immunity levels for individuals in the studied population, and these data can provide a point of comparison for the results of transmission models. In the context of developing an integrated model for measles and rubella transmission, we reviewed the existing measles and rubella literature to identify the results of national serological studies that provided cross-sectional estimates of population immunity at the time of data collection. We systematically searched PubMed, the Science Citation Index, and references we identified from relevant articles published in English. We extracted serological data for comparison to transmission model outputs. For rubella, serological studies of women of child-bearing age provide information about the potential risks of infants born with congenital rubella syndrome. Serological studies also document the loss of maternal antibodies, which occurs at different rates for the different viruses and according to the nature of the induced immunity (i.e., infection or vaccine). The serological evidence remains limited for some areas, with studies from developed countries representing a disproportionate part of the evidence. The collection and review of serological evidence can help program managers identify immunity gaps in the population, which may help them better understand the characteristics of individuals within their populations who may participate in transmission and manage risks.

show abstract

Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996

Cited by 8 publications

References 25 publications

High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?

High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?

Use of M-M-R II outside of the routinely recommended age range – a systematic literature review

Systematic Review of Measles and Rubella Serology Studies

Contact Info

Product

Resources

About